Brean Murray Carret initiates a Buy rating and $24 price target on Insulet PODD as the company presents an attractive growth story with a key approval looming in the near term.
Brean Murray Carret notes, "We are initiating coverage of Insulet (PODD) with a Buy rating. Insulet is uniquely positioned in the $1B insulin pump market as the only supplier of a disposable patch insulin pump, the OmniPod, a highly differentiated product offering which has gained a strong following due to its ease of use and ease of training, among other features. A next gen version of the pump, EROS, finally appears close to FDA clearance, and further improves upon the existing technology ‐ delivering a significant size reduction to wearers and a notable reduction in cost of goods."
PODD closed at $19.11 per share on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in